← back to search

John G. Clohessy

Center for Cancer Research · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Cancer research, Biology, PTEN, Prostate cancer, Tumor microenvironment, and PI3K/AKT/mTOR pathway.
h-index
citations
2,440
works
16
NIH funding
primary concept
email

Recent publications

Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer
Cancer Research 2024cited by 26position: middledoi
PI3K drives the de novo synthesis of coenzyme A from vitamin B5
Nature 2022cited by 98position: middledoi
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Cell 2021cited by 239position: middledoi
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
Communications Biology 2021cited by 28position: middledoi
PDX-derived organoids model in vivo drug response and secrete biomarkers
JCI Insight 2020cited by 126position: middledoi
The Tug1 lncRNA locus is essential for male fertility
Genome biology 2020cited by 113position: middledoi
Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway
Science 2019cited by 337position: middledoi
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita
Nature Genetics 2019cited by 133position: middledoi
An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance
Cell 2018cited by 331position: middledoi
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Nature Genetics 2018cited by 296position: middledoi
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
EMBO Molecular Medicine 2018cited by 180position: middledoi
Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis
Clinical Cancer Research 2018cited by 51position: middledoi
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Cancer Discovery 2017cited by 148position: middledoi
Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma
Molecular Cell 2016cited by 101position: middledoi
Vulnerabilities of <i>PTEN</i> – <i>TP53</i> -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
Cancer Discovery 2014cited by 89position: middledoi
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer
Nature Genetics 2013cited by 144position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Pier Paolo Pandolfi · The Ohio State University5 papers (2013–2020)Sabina Signoretti · Cancer Research Center3 papers (2013–2018)Lewis C. Cantley · Meyer (China)3 papers (2013–2022) · 3 papers (2013–2018)John M. Asara · Harvard University3 papers (2014–2022) · 2 papers (2013–2014)Akash Patnaik · University of Illinois Chicago2 papers (2013–2014)Massimo Loda · Cornell University2 papers (2013–2014)Assaf C. Bester · Hebrew University of Jerusalem2 papers (2018–2020) · 2 papers (2013–2014)Carlos Cordon‐Cardo · Mount Sinai Health System2 papers (2013–2018)Alex Toker · Beth Israel Deaconess Medical Center2 papers (2022–2024)Ming Chen · Sun Yat-sen University Cancer Center2 papers (2014–2018)Xuesong Liu · Shandong University2 papers (2014–2018) · 2 papers (2018–2018) · 2 papers (2013–2014)John L. Rinn · University of Colorado Boulder2 papers (2018–2020)Enrique González‐Billalabeitia · Beth Israel Deaconess Medical Center2 papers (2014–2018)Christopher Ng · Massachusetts Institute of Technology2 papers (2014–2018)Jonah Lee · University of Kentucky1 papers (2024–2024)